Hello Traders-Jeff Bishop Here!
If you’ve been following our updates about MyMD, you know we’ve been focusing primarily on MYMD-1® and its Phase 2 trial as a therapy for delaying aging and prolonging healthy lifespan.
To do this, MYMD-1® is designed to selectively reduce levels of TNF-α in adults.
Why should you care?
Well, TNF-α is believed to contribute to the aging process (sarcopenia) as well as autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis and Crohn’s disease among many others.
TNF-α blockers are among the most prescribed drugs by revenue in the world – a global market worth about $40 billion a year! Major players in this market include Humira (surpassing $20B in revenue in 2021), Enbrel ($4.35B in 2021) and Remicade ($3.2B).
And currently NONE of these TNF-α blockers can be taken ORALLY. Humira and Enbrel involve subcutaneous injections, while Remicade’s is an IV infusion over a period of not less than 2 hours. What a pain (literally)!
In stark contrast, MYMD-1® CAN BE TAKEN ORALLY!
To reiterate, all currently available TNF-α blockers require delivery by injection or infusion — and no approved TNF inhibitor has ever been dosed orally – so MYMD-1® would be the first if successful.
This would be a huge advantage over the other drugs for not only patients but also providers. And who could possibly root against that???!!!
|
Injection, infusion or pill…hmmm….
So if the potential of MYMD-1® this doesn’t have you jazzed up, perhaps diving into the company’s trading will!
Traders should note that MYMD has been consolidating around the crucial $3.30 support level for about 2-weeks now. It is building energy for the next move.
The stock has held up remarkably well in face of an extremely weak market. This is a very encouraging signal.
Active traders should look for 2 key levels right now: a closing price above $3.45, which is the 5-day moving average. I never like to be a buyer of stocks that can’t hold above the 5-day moving average, so I want to see consistent closes above that level.
I then want to see a break above $3.70 which is above the mid-point of the Keltner channel. To me, that is one of the clearest signals that separate a bullish trend from a bearish one.
This should be an exciting week for MYMY so keep it on your radar!
|
62 Calef Hwy #233 Lee, New Hampshire 03861 United States
Questions or concerns about our products? Email Support@360.com © Copyright 2022, RagingBull – Refund Policy – Privacy Policy – Terms & Conditions
|
|
*THIS IS AN ISSUER-PAID ADVERTISEMENT, SEE DISCLOSURE BELOW
*ISSUER-PAID ADVERTISEMENT. MyMD, Inc. (“MYMD” or the “Company”) HAS PAID OR
WILL PAY SHERWOOD VENTURES, LLC (“Sherwood”) TWENTY-THOUSAND DOLLARS USD PER MONTH FOR THREE MONTHS (THE “INITIAL TERM”) IN CASH, SHARES OF RESTRICTED COMMON STOCK WITH A VALUE OF ONE-HUNDRED-FIFTY THOUSAND DOLLARS, AND WARRANTS VALUED AT ISSUANCE OF SEVENTY-FIVE THOUSAND DOLLARS FOR MARKETING SERVICES INCLUDING COMMUNICATING TO THE PUBLIC ABOUT THE COMPANY THROUGH SHERWOOD’S AFFILIATE RAGINGBULL.COM, LLC (“RAGING BULL”), AMONG OTHERS. THIS ADVERTISEMENT IS PART OF THOSE ISSUER-PAID MARKETING SERVICES. FOR DETAILED COMPENSATION AND MORE INFORMATION, PLEASE SEE THE FULL DISCLOSURE LOCATED AT HTTPS://BOARDROOMINVESTING.COM/MYMD-DISCLAIMER.
|
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer.
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of RagingBull.com, LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
|
|
.gif)
